Lotus Eye Hospital and Institute (LOTUSEYE)₹100.05−3.79%Hospital
In the Jun 2026 quarter (standalone), Lotus Eye Hospital and Institute reported sales of ₹17.12 Cr, up 26.2% from Jun 2025, and net profit of ₹0.62 Cr, up 12.7% year on year. For the year to Mar 2026, sales were ₹53.89 Cr and net profit ₹0.09 Cr.
Company filings, standalone accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 12.77 | 12.07 | 10.93 | 12.95 | 12.97 | 12.30 | 11.56 | 13.57 | 13.09 | 13.61 | 13.66 | 17.12 |
| Expenses | 10.94 | 10.46 | 10.13 | 11.24 | 11.78 | 11.47 | 11.69 | 12.06 | 12.28 | 12.90 | 13.15 | 14.12 |
| Operating Profit | 1.80 | 1.57 | 0.75 | 1.65 | 1.14 | 0.78 | −0.16 | 1.47 | 0.76 | 0.65 | 0.47 | 2.94 |
| OPM % | 14.2% | 13.1% | 7.0% | 12.8% | 8.9% | 6.4% | −1.5% | 10.9% | 5.9% | 4.8% | 3.5% | 17.3% |
| Other Income | 0.27 | 0.33 | 0.39 | 0.30 | 0.26 | 0.21 | 0.51 | 0.18 | 0.26 | 0.23 | 0.46 | 0.20 |
| Interest | 0.00 | 0.03 | 0.02 | 0.05 | 0.07 | 0.12 | 0.08 | 0.11 | 0.11 | 0.28 | 0.32 | 0.50 |
| Depreciation | 0.88 | 0.97 | 1.11 | 1.05 | 1.22 | 1.30 | −0.57 | 0.81 | 0.84 | 0.97 | 1.09 | 1.63 |
| Profit before tax | 1.20 | 0.91 | 0.02 | 0.86 | 0.12 | −0.44 | 0.85 | 0.74 | 0.08 | −0.38 | −0.49 | 1.02 |
| Tax % | 28.5% | 26.6% | −200.0% | 28.2% | 9.1% | −44.2% | 70.2% | 24.6% | −71.5% | −29.8% | −33.4% | 39.6% |
| Exceptional items | 0.02 | −0.02 | −0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −0.02 | 0.00 |
| Net Profit | 0.86 | 0.67 | 0.03 | 0.63 | 0.09 | −0.25 | 0.26 | 0.55 | 0.13 | −0.27 | −0.33 | 0.62 |
| EPS (Rs) | 0.40 | 0.31 | 0.00 | 0.29 | 0.04 | −0.11 | 0.11 | 0.25 | 0.05 | −0.12 | −0.14 | 0.28 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 31.24 | 34.11 | 38.19 | 38.57 | 40.74 | 32.45 | 39.08 | 47.18 | 48.42 | 49.75 | 53.89 | 57.48 |
| Expenses | 27.18 | 30.64 | 33.70 | 35.27 | 36.60 | 28.75 | 33.04 | 39.39 | 41.59 | 46.02 | 50.39 | 52.45 |
| Operating Profit | 3.98 | 3.32 | 4.33 | 3.21 | 3.97 | 3.61 | 5.91 | 7.67 | 6.62 | 3.55 | 3.37 | 4.82 |
| OPM % | 12.8% | 9.8% | 11.4% | 8.4% | 9.8% | 11.1% | 15.2% | 16.3% | 13.7% | 7.1% | 6.3% | 8.4% |
| Other Income | 0.57 | 0.67 | 0.90 | 0.67 | 0.20 | 0.83 | 0.87 | 1.14 | 1.30 | 1.30 | 1.17 | 1.15 |
| Interest | 0.15 | 0.14 | 0.17 | 0.20 | 0.23 | 0.13 | 0.20 | 0.19 | 0.19 | 0.47 | 0.85 | 1.21 |
| Depreciation | 4.43 | 3.43 | 3.36 | 3.05 | 2.49 | 2.32 | 2.49 | 2.97 | 3.72 | 3.00 | 3.74 | 4.53 |
| Profit before tax | −0.04 | 0.43 | 1.71 | 0.64 | 1.46 | 2.00 | 4.10 | 5.66 | 4.02 | 1.39 | −0.06 | 0.23 |
| Tax % | −400.1% | −7.2% | −2.4% | −12.8% | 26.8% | 21.1% | 27.1% | 27.7% | 27.4% | 46.3% | −280.1% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −0.02 |
| Net Profit | 0.11 | 0.45 | 1.76 | 0.72 | 1.07 | 1.58 | 2.99 | 4.09 | 2.92 | 0.75 | 0.09 | 0.15 |
| EPS (Rs) | 0.04 | 0.20 | 0.83 | 0.33 | 0.50 | 0.74 | 1.42 | 1.95 | 1.39 | 0.35 | 0.03 | 0.07 |
| Dividend payout % | 0.0% | 236.3% | 59.3% | 0.0% | 0.0% | 66.2% | 34.9% | 25.4% | 0.0% | 0.0% | 0.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 20.86 | 20.85 | 20.85 | 20.85 | 20.87 | 20.86 | 20.86 | 20.87 | 20.88 | 20.85 | 20.88 | 20.86 |
| Reserves | 28.67 | 28.81 | 29.34 | 29.94 | 29.43 | 30.55 | 31.99 | 33.90 | 36.89 | 38.72 | 39.35 | 39.49 |
| Borrowings | 0.82 | 0.65 | 0.47 | 0.28 | 0.21 | 0.31 | 0.39 | 1.23 | 0.66 | 1.10 | 3.42 | 15.78 |
| Other Liabilities | 6.17 | 4.65 | 4.43 | 7.25 | 6.15 | 6.51 | 6.10 | 5.72 | 4.91 | 6.14 | 6.11 | 6.62 |
| Total Liabilities | 56.52 | 54.96 | 55.09 | 58.32 | 56.66 | 58.23 | 59.34 | 61.72 | 63.34 | 66.81 | 69.76 | 82.75 |
| Fixed Assets | 47.13 | 43.67 | 41.43 | 42.59 | 44.26 | 42.76 | 40.61 | 44.15 | 44.28 | 48.80 | 54.22 | 65.92 |
| CWIP | 0.26 | 0.41 | 0.64 | 0.28 | 0.28 | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.00 | 0.08 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 9.13 | 10.88 | 13.02 | 15.45 | 12.12 | 15.47 | 18.73 | 17.57 | 19.06 | 17.94 | 15.54 | 16.75 |
| Inventories | 3.08 | 2.77 | 1.79 | 2.38 | 2.15 | 2.10 | 1.77 | 2.30 | 2.78 | 3.20 | 3.82 | 3.82 |
| Trade receivables | 0.36 | 0.52 | 0.69 | 1.15 | 0.77 | 0.67 | 0.75 | 0.63 | 1.18 | 1.27 | 1.33 | 1.22 |
| Cash & equivalents | 0.51 | 2.46 | 3.39 | 3.80 | 2.58 | 7.01 | 9.90 | 8.84 | 8.40 | 7.03 | 4.14 | 3.82 |
| Total Assets | 56.52 | 54.96 | 55.09 | 58.32 | 56.66 | 58.23 | 59.34 | 61.72 | 63.34 | 66.81 | 69.76 | 82.75 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 2.38 | 3.39 | 2.98 | 5.80 | 4.21 | 4.99 | 2.74 | 4.42 | 4.40 | 5.70 | 2.71 | 3.03 |
| Cash from investing activity | −4.64 | −0.84 | −1.05 | −3.85 | −4.00 | −0.67 | 0.48 | −3.93 | −2.18 | −4.62 | −6.12 | −12.34 |
| Cash from financing activity | 1.86 | −0.59 | −0.26 | −1.52 | −1.42 | 0.14 | −0.33 | −1.59 | −1.72 | −3.41 | −1.61 | 9.04 |
| Net cash flow | −0.41 | 1.97 | 1.67 | 0.42 | −1.23 | 4.44 | 2.91 | −1.11 | 0.50 | −2.36 | −5.05 | −0.33 |
| Capex | 5.48 | 0.99 | 1.21 | 4.27 | 4.68 | 2.41 | 0.47 | 4.67 | 3.09 | 5.56 | 4.82 | 12.94 |
| Free cash flow | −2.37 | 2.27 | 1.54 | 1.57 | −0.48 | 3.53 | 2.60 | −0.24 | 1.29 | 0.11 | −2.10 | −10.00 |
| CFO / OP % | 109.1% | 85.0% | 92.1% | 142.0% | 134.0% | 132.0% | 84.0% | 89.0% | 76.0% | 101.0% | 94.0% | 99.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 4 | 6 | 7 | 11 | 7 | 6 | 8 | 6 | 9 | 10 | 10 | 8 |
| Inventory days | 122 | 113 | 60 | 79 | 128 | 124 | 139 | 150 | 154 | 170 | 194 | 84 |
| Days payable | 124 | 105 | 86 | 129 | 166 | 169 | 220 | 230 | 172 | 183 | 169 | 70 |
| Cash conversion cycle | 0 | 13 | −21 | −41 | −33 | −41 | −75 | −76 | −12 | −5 | 32 | 20 |
| Working capital days | −20 | −9 | −9 | −26 | −15 | −21 | −24 | −16 | 9 | 6 | 0 | −12 |
| ROCE % | −4.2% | 0.2% | 1.2% | 3.6% | 1.7% | 4.7% | 3.9% | 7.9% | 10.3% | 7.1% | 3.0% | 1.2% |
For the Jun 2026 quarter, Lotus Eye Hospital and Institute reported sales of ₹17.12 Cr, up 26.2% year on year and net profit of ₹0.62 Cr, up 12.7% year on year. The operating margin was 17.3%.
Lotus Eye Hospital and Institute's sales for the year to Mar 2026 were ₹53.89 Cr; over the last twelve months they were ₹57.48 Cr.
Net profit for the year to Mar 2026 was ₹0.09 Cr, and ₹0.15 Cr over the last twelve months. Earnings per share over the same trailing period were ₹0.07.
Lotus Eye Hospital and Institute reported borrowings of ₹15.78 Cr at Mar 2026, against cash and equivalents of ₹3.82 Cr.
Cash from operations was ₹3.03 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹10 Cr.